Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of moderate to severe persistent asthma (according to GINA 2002 guidelines)~* FEV1 \> 40% and \< 80% of predicted normal post-bronchodilator (and at least 0.7 L absolute value)~* Patients already treated for at least 2 months with an association of inhaled corticosteroids plus LABA at doses of:~  750 - 1000 µg beclomethasone dipropionate or equivalent (ICSs) 24 µg formoterol or 100 µg salmeterol (LABAs)~* Or patients naïve of LABA already treated for at least 2 months with inhaled corticosteroids (doses as above) associated with a daily use of SABA and/or with clinical symptoms \> 3 times in the week prior to inclusion~* A documented positive response to the reversibility test.~Exclusion Criteria:~* Pregnant or lactating females or women of childbearing potential without any efficient contraception.~* Heavy smokers defined as smoking for \> 10 pack years.~* Evidence of asthma exacerbation causing an hospitalisation or requiring treatment with oral/parenteral corticosteroids or evidence of symptomatic airways infection in the 4 weeks prior to inclusion (3 months for slow-release corticosteroids).~* Seasonal asthma or asthma occurring only during episodic exposure to an allergen or occupational chemical sensitizer.~* Clinically significant or unstable concomitant diseases, including clinically significant laboratory abnormalities.~* Patients with an abnormal QTc interval value in the ECG test, defined as \> 450 msec in males or \> 470 msec in females.~* Evidence of asthma worsening during the week preceding randomisation (e.g. PEF variability \> 30% during 2 consecutive days, SABA use \> 8 puffs/day during 2 consecutive days, nocturnal awakenings due to asthma symptoms during 3 consecutive days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- beclometasone /formoterol (Type: EXPERIMENTAL): beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
- Beclomethasone (Type: ACTIVE_COMPARATOR): Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
- Formoterol powder 12 µg/unit dose (Type: ACTIVE_COMPARATOR): Formoterol powder 12 µg/unit dose (Foradil™)

Based on this trial design, predict the completion outcome and termination type (if applicable).